Dr. Frank Hensel
Principal
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2015 |
| my focus | Drug development |
| my background | PhD in biology, founder of a biotech company |
CV
Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €
Four questions for …
What has been your most important milestone so far?
Having founded a startup myself and having gone through all the ups and downs with it over years.
What fascinates you about pre-seed/seed phases?
You can still move and structure a lot in the seed sector. No two cases are the same and every investment is a new challenge.
What do you like most about your job?
Interaction with great scientists and interesting technologies that can be provided to patients through collaboration with investors.
What inspires you outside of work?
A few hours on the racing bike clear your head and give you time to think.
My success stories in the HTGF portfolio
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge …
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
Computomics is a spin-off of the University of Tübingen and the Max Planck Institute for Developmental Biology. Computomics was founded in 2012, when it became clear that a breakthrough in …
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
Guided to exit
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
Custom Cells manufactures customer-specific acculumators and intermediate products based on lithium technology.
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
Recent posts
Zum Artikel
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
Zum Artikel
Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing
Zum Artikel
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
Zum Artikel
Social Media & contact
LinkedIn
Dr. Frank Hensel
Profil